Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Skin
  4. Back
  5. Dermatology
  6. Dupilumab for moderate to severe Atopic Dermatitis (Eczema) (666)

Dupilumab for moderate to severe Atopic Dermatitis (Eczema) (666)

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 01/10/2025

Next review date: 31/10/2028

Author(s): Alison MacDonald.

Version: 3

Approved By: Medicines Utilisation Subcommittee of ADTC

Document Id: 666

References

1.Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC,Weisman J, Pariser D, et al. Long-termmanagement of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-303.

2.Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials ofDupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-48.

3.de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, et al. Dupilumab with concomitant topicalcorticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2017.

4.Scottish Medicines Consortium (SMC) (2015). Omalizumab 150mg solution for injection (Xolair®) SMC No.(1017/14). Glasgow: SMC. [Online]
https://www.scottishmedicines.org.uk/media/3751/dupilumab-dupixent-final-august-2018-for-website.pdf [Accessed 03/10/18]